Abstract
Objectives It is unclear whether patients with hypertension are more likely to be infected with SARS-COV-2 than the general population and whether there is a difference in the severity of COVID-19 pneumonia in patients who have taken ACEI/ARB drugs to lower blood pressure compared to those who have not.
Methods This observational study included data from all patients with clinically confirmed COVID-19 who were admitted to the Hankou Hospital, Wuhan, China between January 5 and March 8, 2020. Data were extracted from clinical and laboratory records. Follow-up was cutoff on March 8, 2020.
Results A total of 274 patients, 75 with hypertension and 199 without hypertension, were included in the analysis. Patients with hypertension were older and were more likely to have pre-existing comorbidities, including chronic renal insufficiency, cardiovascular disease, diabetes mellitus, and cerebrovascular disease than patients without hypertension. Moreover, patients with hypertension tended to have higher positive COVID-19 PCR detection rates. Patients with hypertension who had previously taken ACEI/ARB drugs for antihypertensive treatment have an increased tendency to develop severe pneumonia after infection with SARS-COV-2 (P = 0.064).
Conclusions COVID-19 patients with hypertension were significantly older and were more likely to have underlying comorbidities, including chronic renal insufficiency, cardiovascular disease, diabetes mellitus, and cerebrovascular disease. Patients with hypertension who had taken ACEI/ARB drugs for antihypertensive treatment have an increased tendency to develop severe pneumonia after infection with SARS-COV-2. In future studies, a larger sample size and multi-center clinical data will be needed to support our conclusions.
- COVID-19
- angiotensin-converting enzyme 2
- hypertension
- ACEI/ARB
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Natural Science Foundation of China Grant 81871604 and 81871604; the Natural Science Foundation of Guangdong Province, China, Grants 2020A151501361 and 2017A030313590; the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University, Guangzhou, China, Grant 2016J011.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations
Conflicts of interest The authors declare no conflicts of interest.
Funding This work was supported by the Natural Science Foundation of China Grant 81871604 and 81871604; the Natural Science Foundation of Guangdong Province, China, Grants 2020A151501361 and 2017A030313590; the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University, Guangzhou, China, Grant 2016J011.
Ethics approval This study was approved by the National Health Commission of China and the Ethics Commission of Hankou Hospital (hkyy2020-005).
Consent The Ethics Commission of Hankou Hospital waived the requirement for obtaining informed consent.
Availability of data and material None.
Authors’ contributions Z.C. and Q.H. contributed substantially to the conception and design of the study. Q.H. and Z.Z. drafted and provided critical revision of the article. Z.C., T.S., and F.W. acquired the primary data. Y.Z. and T.S. analyzed and interpreted the data. H.L., J.H., and W.S. analyzed the imaging data. All the authors provided final approval of the version submitted for publication.
Authors’ email addresses Zhenhua Zeng: zhenhuazeng.2008{at}163.com, Tong Sha: shatong_smu{at}163.com, Yuan Zhang: m15626182275{at}163.com, Feng Wu: wishuhappy{at}126.com, Hongbin Hu: hobewoos{at}163.com, Haijun Li: lhj03{at}qq.com, Jiafa Han: 781571340{at}qq.com, Wenhong Song: 894705800{at}qq.com, Qiaobing Huang: bing{at}smu.edu.cn, Zhongqing Chen: zhongqingchen2008{at}163.com
Data Availability
None
Abbreviations and symbols
- COVID-19
- Coronavirus disease
- ACE2
- Angiotensin-converting enzyme 2
- LDH
- Lactate dehydrogenase
- OR
- Odds ratio
- CT
- Computed tomography
- ARDS
- Acute respiratory distress syndrome
- RAAS
- Renin-angiotensin-aldosterone system
- SCr
- Serum creatinine
- Ang II
- Angiotensin II
- SARS
- Severe acute respiratory syndrome
- SARS-CoV
- Severe acute respiratory syndrome coronavirus
- Ang I
- Angiotensin I
- rhuACE2
- Human recombinant ACE 2
